Indication

Osteoporosis in male patient

Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures. Read more about Osteoporosis in male patient

63 drugs 52 manufacturers

Advertisement

Drugs that treat it

Common Osteoporosis in male patient therapies.

Showing 46–54 of 63 drugs

TERIPARATIDE

OSTEOPOROSIS AGENTS·GLUCOCORTICOID-INDUCED OSTEOPOROSIS·+2
TEVA USA

ALENDRONATE SODIUM

OSTEOPOROSIS AGENTS·POSTMENOPAUSAL OSTEOPOROSIS·+1
Hikma Pharmaceuticals USA
Filter & compare in the drug finder →Opens the drug finder with Osteoporosis in male patient preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Osteoporosis in male patient.

Osteoporosis in male patients is a systemic metabolic bone disease characterized by compromised bone strength, low bone mineral density, and microarchitectural deterioration of skeletal tissue, which leads to heightened bone fragility and susceptibility to low-trauma fractures.

In men, the condition typically arises from age-related decreases in osteoblastic bone formation, progressive cortical thinning, and declining bioavailable sex steroids, though a substantial proportion of cases stem from secondary etiologies such as hypogonadism, prolonged glucocorticoid exposure, excessive alcohol intake, or androgen deprivation therapy.

Clinically, it is diagnosed by a low-trauma fragility fracture or a bone mineral density T-score of -2.5 or lower at the spine or hip, carrying significant morbidity and higher post-fracture mortality rates compared to female counterparts.

Personalize your experience

Follow Osteoporosis in male patient and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it